ABIVAX Société Anonyme (NASDAQ:ABVX) Given “Market Outperform” Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of ABIVAX Société Anonyme (NASDAQ:ABVX) in a report issued on Friday morning,Benzinga reports. JMP Securities currently has a $33.00 price objective on the stock.

Separately, Citizens Jmp raised ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Stock Performance

Shares of ABVX opened at $6.38 on Friday. ABIVAX Société Anonyme has a twelve month low of $6.26 and a twelve month high of $17.02. The firm’s 50-day moving average is $8.38 and its two-hundred day moving average is $10.46.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Large investors have recently bought and sold shares of the stock. GAMMA Investing LLC purchased a new stake in shares of ABIVAX Société Anonyme in the fourth quarter valued at $29,000. BNP Paribas Financial Markets lifted its holdings in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares in the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after purchasing an additional 80,807 shares during the period. abrdn plc boosted its position in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.